文献速递炎症性肠病

抗TL1A抗体PF-06480605治疗溃疡性结肠炎的2a期单臂研究

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-06-12

TUSCANY研究为2a期多中心单臂开放标签试验,评估PF-06480605治疗中重度溃疡性结肠炎的安全性和疗效。50例受试者接受500 mg静脉给药每2周一次共7剂,第14周内镜改善率38.2%具有统计学显著性,安全性可接受,但82%产生抗药抗体。

要点

  • PF-06480605在中重度UC中第14周内镜改善率达38.2%,具统计学显著性。
  • 安全性可接受,最常见不良事件为UC疾病加重和关节痛(各6例)。
  • 82%受试者产生抗药抗体,10%产生中和抗体,需关注免疫原性。

核心结论

  • PF-06480605在中重度UC受试者中显示可接受的安全性及具统计学显著性的内镜改善,支持扩大样本进一步研究。

研究设计与样本

  • 2a期多中心单臂开放标签研究(TUSCANY),纳入50例中重度UC受试者,42例完成。
  • 受试者接受500 mg静脉PF-06480605每2周一次共7剂,随访3个月。

主要发现

  • 109例治疗中出现的不良事件中18例与治疗相关,最常见为UC疾病加重和关节痛(各6例)。
  • 报告4例严重不良事件,无死亡及恶性肿瘤。
  • 第14周内镜改善(Mayo内镜子评分=0或1)率为38.2%(per protocol人群)。
  • 治疗后组织学显示轻微病变:Robarts组织病理指数≤5者33.3%,Geboes指数≤3.2者47.6%。

关键数值与推荐

  • 主要疗效终点第14周内镜改善率38.2%(per protocol人群,均匀最小方差无偏估计)。
  • 组织学评估:Robarts组织病理指数≤5为33.3%,Geboes指数≤3.2为47.6%。

临床怎么用

  • PF-06480605可作为中重度UC的潜在治疗选择,但需在更大样本中进一步验证。
  • 治疗期间需监测疾病加重和关节痛等不良事件及抗药抗体产生。

局限性

  • 单臂开放标签设计,无对照组,样本量50例,结果需更大规模随机对照研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: An immune component of inflammatory bowel disease is up-regulated tumor necrosis factor-like ligand 1A (TL1A). Anti-TL1A antibodies such as PF-06480605, a fully human immunoglobulin G1 monoclonal antibody, may have therapeutic potential. METHODS: This Phase 2a, multicenter, single-arm, open-label study (TUSCANY) evaluated safety, tolerability, efficacy, pharmacokinetics, and immunogenicity in PF-06480605-treated participants with moderate to severe ulcerative colitis (UC). Participants received 500 mg intravenous PF-06480605 every 2 weeks, 7 doses total, with a 3-month follow-up period. Primary safety and efficacy endpoints were the incidence of adverse events (AEs) and week 14 endoscopic improvement (EI) (Mayo endoscopic subscore = 0 or 1), respectively. Secondary endpoints included total soluble TL1A (free/drug-bound) (sTL1A), incidence of anti-drug and neutralizing antibodies, PF-06480605 concentrations, and changes in fecal calprotectin and high-sensitivity C-reactive protein. Histology was assessed at week 14. RESULTS: The study enrolled 50 participants; 42 completed. Of 109 treatment-emergent AEs, 18 were treatment-related. The most common AEs were UC disease exacerbation and arthralgia (6 participants each). Four serious AEs, no deaths, and no malignancies were reported. Week 14 EI was observed in a statistically significant proportion of participants (38.2% [uniformly minimum-variance unbiased estimator, per protocol population]). Minimal histologic disease was observed after treatment (Robarts Histopathology Index ≤5: 33.3%; Geboes Index ≤3.2: 47.6%). sTL1A increase over time from baseline indicated sustained target engagement. Forty-one participants (82%) tested positive for anti-drug antibodies and 5 (10%) for neutralizing antibodies. CONCLUSIONS: PF-06480605 demonstrated an acceptable safety profile and statistically significant EI in participants with moderate to severe UC, warranting further study in a larger participant cohort. Tissue histopathology analyses support this conclusion. TRIAL REGISTRATION NUMBER: https://clinicaltrials.gov/NCT02840721.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Danese S, Klopocka M, Scherl EJ, et al. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol. 2021. PMID: 34126262. doi:10.1016/j.cgh.2021.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。